J. K. von Frijtag Drabbe Künzel

发表

2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists.

A. IJzerman, T. Mulder-Krieger, H. de Vries, 2008, Journal of medicinal chemistry.

Allosteric modulation, thermodynamics and binding to wild‐type and mutant (T277A) adenosine A1 receptors of LUF5831, a novel nonadenosine‐like agonist

A. IJzerman, T. Mulder-Krieger, L. Heitman, 2006, British journal of pharmacology.

Radical scavenging properties of adenosine and derivatives in vitro

A. IJzerman, J. K. von Frijtag Drabbe Künzel, J. van der Zee, 1996 .

Putative role of the adenosine A3 receptor in the antiproliferative action of N6-(2-isopentenyl)adenosine

A. IJzerman, T. Mulder-Krieger, H. de Vries, 2011, Purinergic Signalling.

2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists.

A. IJzerman, T. Mulder-Krieger, J. K. von Frijtag Drabbe Künzel, 2006, Journal of Medicinal Chemistry.

Synthesis and biological evaluation of 2-aminothiazoles and their amide derivatives on human adenosine receptors. Lack of effect of 2-aminothiazoles as allosteric enhancers.

A. IJzerman, T. Mulder-Krieger, A. Göblyös, 2005, Bioorganic & medicinal chemistry.

5'-substituted adenosine analogs as new high-affinity partial agonists for the adenosine A1 receptor.

A. IJzerman, J. K. von Frijtag Drabbe Künzel, A. Lorenzen, 1998, Journal of medicinal chemistry.

N6,C8-distributed adenosine derivatives as partial agonists for adenosine A1 receptors.

N. Veldman, A. Spek, A. IJzerman, 1996, Journal of medicinal chemistry.

Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor.

M. Danhof, A. IJzerman, J. K. von Frijtag Drabbe Künzel, 1995, Journal of medicinal chemistry.

5'-O-alkyl ethers of N,2-substituted adenosine derivatives: partial agonists for the adenosine A1 and A3 receptors.

A. IJzerman, J. K. von Frijtag Drabbe Künzel, P. van der Klein, 2001, Journal of medicinal chemistry.

Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects

M. Danhof, A. IJzerman, J. K. von Frijtag Drabbe Künzel, 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine.

A. IJzerman, T. Mulder-Krieger, J. K. von Frijtag Drabbe Künzel, 2004, Journal of medicinal chemistry.

A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor.

A. IJzerman, T. Mulder-Krieger, J. K. von Frijtag Drabbe Künzel, 2005, Journal of medicinal chemistry.

A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines.

A. IJzerman, T. Mulder-Krieger, J. V. van Veldhoven, 2008, Bioorganic & medicinal chemistry.

N6-cyclopentyl-3'-substituted-xylofuranosyladenosines: a new class of non-xanthine adenosine A1 receptor antagonists.

A. IJzerman, J. K. von Frijtag Drabbe Künzel, P. Herdewijn, 1997, Journal of medicinal chemistry.

2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists.

Thea Mulder-Krieger, Johannes Brussee, A. IJzerman, 2004, Journal of medicinal chemistry.

2-Nitro analogues of adenosine and 1-deazaadenosine: synthesis and binding studies at the adenosine A1, A2A and A3 receptor subtypes.

A. IJzerman, J. K. von Frijtag Drabbe Künzel, G. Koomen, 2000, Bioorganic & medicinal chemistry letters.

Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.

S. Moro, K. Jacobson, A. IJzerman, 1998, Journal of medicinal chemistry.

Interference of linoleic acid fraction in some receptor binding assays.

A. IJzerman, J. K. von Frijtag Drabbe Künzel, K. Ingkaninan, 1999, Journal of natural products.

2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists.

A. IJzerman, T. Mulder-Krieger, J. K. von Frijtag Drabbe Künzel, 2007, Journal of medicinal chemistry.

Inhibition of nucleoside transport proteins by C8-alkylamine-substituted purines.

A. IJzerman, J. K. von Frijtag Drabbe Künzel, Ronald F Spanjersberg, 2005, Journal of medicinal chemistry.

Inhibition of nucleoside transport by new analogues of 4-nitrobenzylthioinosine: replacement of the ribose moiety by substituted benzyl groups.

A. IJzerman, J. K. von Frijtag Drabbe Künzel, B. Sundermann, 2004, Journal of medicinal chemistry.

N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor.

Adriaan P IJzerman, Martin J Wanner, A. IJzerman, 2003, Journal of medicinal chemistry.

Potent antagonists for the human adenosine A2B receptor. Derivatives of the triazolotriazine adenosine receptor antagonist ZM241385 with high affinity

A. IJzerman, J. K. von Frijtag Drabbe Künzel, M. Beukers, 1999 .

2,8-Disubstituted adenosine derivatives as partial agonists for the adenosine A2A receptor.

A. IJzerman, J. K. von Frijtag Drabbe Künzel, M. Gremmen, 2003, Bioorganic & medicinal chemistry.

N6,5'-Disubstituted adenosine derivatives as partial agonists for the human adenosine A3 receptor.

A. IJzerman, J. K. von Frijtag Drabbe Künzel, A. Lorenzen, 1999, Journal of medicinal chemistry.

Synthesis and biological evaluation of disubstituted N6-cyclopentyladenine analogues: the search for a neutral antagonist with high affinity for the adenosine A1 receptor.

A. IJzerman, J. K. von Frijtag Drabbe Künzel, J. Brussee, 2004, Bioorganic & medicinal chemistry.

8-substituted adenosine and theophylline-7-riboside analogues as potential partial agonists for the adenosine A1 receptor.

M. Danhof, A. IJzerman, J. K. von Frijtag Drabbe Künzel, 1995, European journal of pharmacology.

5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors.

A. Spek, A. IJzerman, J. K. von Frijtag Drabbe Künzel, 1999, Journal of medicinal chemistry.

The mouse brain adenosine A1 receptor: functional expression and pharmacology.

A. IJzerman, J. K. von Frijtag Drabbe Künzel, H. Boddeke, 2004, European journal of pharmacology.

Phenyl‐substituted N6‐phenyladenosines and N6‐phenyl‐5′‐N‐ethylcarboxamidoadenosines with high activity at human adenosine A2B receptors

A. IJzerman, J. K. von Frijtag Drabbe Künzel, P. van der Klein, 2000 .

A functional screening of adenosine analogues at the adenosine A2B receptor: a search for potent agonists.

K. Jacobson, A. IJzerman, J. K. von Frijtag Drabbe Künzel, 1998, Nucleosides & nucleotides.

Site-directed mutagenesis of the human adenosine A2A receptor. Critical involvement of Glu13 in agonist recognition.

K. Jacobson, A. IJzerman, J. K. von Frijtag Drabbe Künzel, 1996, European journal of pharmacology.

Partial agonists for adenosine receptors

A. IJzerman, J. K. von Frijtag Drabbe Künzel, R. Mathôt, 1996 .

A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines.

A. IJzerman, T. Mulder-Krieger, J. V. van Veldhoven, 2008, Bioorganic & medicinal chemistry.

Synthesis and biological evaluation of disubstituted N6-cyclopentyladenine analogues: the search for a neutral antagonist with high affinity for the adenosine A1 receptor.

A. IJzerman, J. K. von Frijtag Drabbe Künzel, J. Brussee, 2004, Bioorganic & medicinal chemistry.